ArticleBMC nephrology2025
Role of AT1angiotensin receptor antagonist in pulmonary complications induced by renal ischemia-reperfusion injury in male and female rats.
Article in BMC nephrology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundPulmonary complications following renal ischemia-reperfusion injury (IRI) occur in a gender-dependent manner. Moreover, an imbalance in the renin-angiotensin system (RAS) exacerbates both renal and pulmonary diseases. Overactivation of the classical RAS component the angiotensin type 1 receptor (AT1R) and angiotensin II may worsen renal IRI and remote organ damage, with gender-specific differences. This study aims to investigate the effect of renal IR on lung injury across genders.
methodsSixty Wistar rats (30 females, 30 males) were randomly assigned to three groups within each gender: Sham, IR (Isch), and IR with losartan (AT1R antagonist; Isch). Bilateral renal ischemia was induced for 45 min in all groups except the sham group. After 24 h of reperfusion, blood samples were collected for serum analysis, and kidney and lung tissues were harvested for histopathological examination, as well as assessment of malondialdehyde (MDA), and nitrite levels. The left lung was also weighed to evaluate pulmonary edema.
resultsRenal IR led to notable increases in plasma creatinine, blood urea nitrogen (BUN), MDA levels, and the extent of damage to the kidney and lung tissues in both genders. In female rats, losartan significantly decreased serum BUN (56.87 ± 13.1 vs. 112.9 ± 8.9 in groups Isch L and Isch), attenuated kidney scores (7.6 ± 1.3 vs. 12.8 ± 1.2 in groups Isch L and Isch), and increased renal (0.18 ± 0.02 vs. 0.10 ± 0.01 in groups Isch L and sham) and pulmonary nitrite concentrations (0.37 ± 0.07 vs. 0.22 ± 0.009 in groups Isch L and sham) following IR. On the other hand, serum MDA levels increased significantly in males treated with losartan (2.6 ± 0.11 vs. 3.9 ± 0.4 in groups sham and Isch L). Furthermore, losartan mitigated IR-induced lung injury in females (6.5 ± 0.6 vs. 8.3 ± 0.3 in groups Isch L and Isch), whereas it had no significant effect in males.
conclusionsOur findings suggest that AT1R blockade with losartan confers a gender-dependent protective effect. Specifically, losartan may mitigate IR-induced renal and pulmonary damage in females, potentially through modulation of the nitric oxide pathway and attenuation of oxidative stress.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.